Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

News & Events

Early ear infections linked to higher risk of future problems: study

Researchers have found kids who experience repeat ear infections in infancy have a much higher risk of ongoing problems with ear infections in later childhood

Our research

At the Wesfarmers Centre, we undertake research in five key areas of infections and immunisation to assist in children's health.

Hospital-based research

Review the hospital-based research that the Wesfamers Centre of Vaccines & Infectious Diseases conducts.

AusVaxSafety (previously FAST)

The aim of the study is the early identification of problems with the current flu vaccines, and providing parents and professionals with up to date information.

2020 VTG Christmas Update

Coming up in 2021 Contact us We have a a study to suit every age range in 2021!  From babies at just six weeks for the FluBub Study, through to

News & Events

Rheumatic Heart Disease Endgame Strategy: what does it mean to community?

Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).

Research

Improving primary care for Aboriginal and Torres Strait Islander people with rheumatic heart disease: What can I do?

Acute rheumatic fever and rheumatic heart disease disproportionately affect Aboriginal and Torres Strait Islander people in Australia, with devastating impacts on morbidity, mortality and community wellbeing. Research suggests that general practitioners and primary care staff perceive insurmountable barriers to improving clinical outcomes, including the need for systemic change outside their scope of practice.

Research

ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial

SARS-CoV-2 infection is associated with a significant risk of hospitalisation, death, and prolonged impact on quality of life. Evaluation of new treatment options and optimising therapeutic management of people hospitalised with SARS-CoV-2 infection remains essential, but rapid changes in pandemic conditions and potential therapies have limited the utility of traditional approaches to randomised controlled trials.